Some patients report skin changes associated with rapid weight loss , which is a therapeutic effect of GLP-1 medications used for weight management
Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function
44 Orforglipron In a phase 2, randomized, double-blind trial, daily oral orforglipron (12, 24, 36, or 45 mg) for 36 weeks led to weight reductions of 9.414.7% in adults with pre-obesity or obesity (without diabetes), compared to 2.3% with placebo, and showed no signs of plateau (Table 2)
Helping people limit compulsive eating and drinking, motivate movement, and reduce chronic inflammation which we know GLP-1s can do we promote a higher quality life
doi:10.2147/ijwh.S165474
Cancer Research: The peptide shows significant potential as a tumor suppressor in cancer therapy by targeting and eliminating senescent cancer cells, which often arise from DNA damage and contribute to cancer progression and recurrence